News

The stock's fall snapped a three-day winning streak.
The U.S. Centers for Disease Control and Prevention has ended its emergency response to the H5N1 bird flu outbreak, a move ...
The FDA's Dr. Vinay Prasad said that he disagreed with the agency's career vaccine reviewers about COVID shot approvals.
Novavax (NVAX) closed the most recent trading day at $6.61, moving -2.79% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.79% for the day. At the ...
Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...
Writing in JAMA, four former government officials warn that the Trump administration’s involvement in delaying the approval ...
The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...
For many, Novavax is #1 – the one and only COVID vaccine they would consider. This enthusiasm for Novavax isn’t new. As far back as 2022, news reports described a kind of Novavax fan club ...
Federal documents show he disagreed with conclusions the benefits outweighed the risk of side effects, which are rare.
Novavax released its FY22 earnings last week and the news was not good, with the company reporting losses. Click here to read my most recent analysis of NVAX. Skip to content.
Novavax expects revenue of $4 billion to $5 billion this year in global sales, Trizzino said, noting "this is not just a pandemic question, it's an ongoing vaccination question." ...
Novavax was authorized by the FDA for use in adults and children 12 and older, so younger kids can't get this vaccine. But for most adults, which COVID vaccine you should choose depends on your ...